Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q1 2022 Earnings Presentation
8 slides from Agilent Technologies's earnings presentation, Feb 22, 2022
Slide 1: Agilent Technologies Q1'22 Results Presentation
Agilent Technologies Q1’22 Results Presentation
Slide 2: Safe Harbor
Safe Harbor These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth
Slide 3: Agilent Results Q1'22
Agilent Results Q1’22 Scale and leading technology across Analytical Laboratories and Dx & Clinical markets Q1’22 Financial Metrics Q1’22 Highlights • Revenues: $1.67B, +8.9% y/y • Growth was driven by strength in Pharma and BioPharma, core(1)(2),+8.1% reported (-1.3% FX, ongoing momentum in Chemica
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Q1 core revenue performance reflected strength in Instrumentation, Informatics, and Consumables key end markets led by Pharma and Chemical & for Analytical Laboratories Energy. Momentum across all platforms led by Consumables, Spectroscopy, LC, and LC/M
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • ACG growth in Q1 was led by strong contract Services revenue across the portfolio, and demonstrated resiliency by delivering positive growth in every one of our regions and end markets • Q1’22 Operating Margin for the quarter was 25.2%(2), up 210
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Q1 core revenue growth was led by another Pathology, Genomics, and Nucleic Acid Manufacturing outstanding performance from NASD and strong double-digit growth in our genomics and cancer diagnostics businesses. • Our Resolution Bioscience team achieved a major N
Slide 7: Growth in a $63B+ Market – Q1'22 Results by End Market
Growth in a $63B+ Market – Q1’22 Results by End Market Continued momentum in Pharma, C&E, and Dx & Clinical markets Analytical Laboratory End Markets Q1’22 revenues: +9% y/y on core(2) basis Pharma & Biotech: Up 17% on continued BioPharma strength in the US, Europe, and China Chemical & Energy
Slide 8: Q2'22 and FY22 Guidance and Forward-looking Considerations
Q2’22 and FY22 Guidance and Forward-looking Considerations Based on January 31, 2022 Exchange Rates Q2’22 Guidance (1) FY22 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,595 $1,625 Net Revenue ($M) $6,670 $6,730 Y/Y Core Revenue Growth (2) 6.5% 8.5% Y/Y Core Revenue Growth (2) 7